The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety

The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety

Possibly through its effects on glia, the peroxisome proliferator-activated gamma receptor (PPARγ) agonist pioglitazone (PIO) has been shown to alter the effects of heroin in preclinical models. Until now, these results have not been assessed in humans. Heroin-dependent participants were randomized...

Full description

Bibliographic Details
Main Authors: Bisaga, A. (Author), Ciccocioppo, R. (Author), Comer, S.D (Author), Doernberg, M. (Author), Jones, J.D (Author), Madera, G. (Author), Manubay, J.M (Author), Metz, V.E (Author), Mogali, S. (Author)
Format: Article
Language:English
Published: Routledge 2018
Subjects:
Abuse potential
adult
Adult
antidiabetic agent
anxiety
Anxiety
Article
association
buprenorphine
Buprenorphine
buprenorphine plus naloxone
controlled study
craving
Craving
diamorphine
drug craving
drug effect
drug efficacy
drug safety
drug self administration
drug therapy
etiology
female
Female
glia
heroin
heroin dependence
Heroin Dependence
human
human experiment
Humans
Hypoglycemic Agents
male
Male
middle aged
Middle Aged
miosis
normal human
opioids
peroxisome proliferator activated receptor gamma
pioglitazone
Pioglitazone
placebo
PPAR gamma
psychology
questionnaire
randomized controlled trial
reinforcement
Reinforcement (Psychology)
scoring system
Self Administration
single blind procedure
Single-Blind Method
task performance
treatment outcome
visual analog scale
visual stimulation
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items